Subscribe
shutterstock_390812083_gino_santa_maria
Gino Santa Maria / Shutterstock.com
9 December 2019AmericasRory O'Neill

Sanders calls on USPTO to block Gilead patent extension

US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office (USPTO) to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy (tenofovir alafenamide/embicitrane).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US government sues Gilead for patent infringement over HIV drugs
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
Senators demand USPTO probe into Gilead allegations
16 December 2019   The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
US government sues Gilead for patent infringement over HIV drugs
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
Senators demand USPTO probe into Gilead allegations
16 December 2019   The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

More on this story

Americas
US government sues Gilead for patent infringement over HIV drugs
7 November 2019   The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
Senators demand USPTO probe into Gilead allegations
16 December 2019   The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

More features

Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner
Apple wins just $250 in Masimo smartwatch clash
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
Big Pharma counsel embrace AI but data and legal risks loom